PMID- 12372922
OWN - NLM
STAT- MEDLINE
DCOM- 20030407
LR  - 20171101
IS  - 1424-8832 (Print)
IS  - 1424-8832 (Linking)
VI  - 32
IP  - 3
DP  - 2002 May-Jun
TI  - Effect of low-molecular-weight heparin on potassium homeostasis.
PG  - 107-10
AB  - BACKGROUND: Low-molecular-weight heparins (LMWHs) are being preferred to 
      unfractionated heparin (UFH) because of their superior convenience and a 
      comparable or slightly better toxicity profile. Whether LMWH has an inhibitory 
      effect on aldosterone that causes hyperkalemia is yet uncertain. METHODS: 
      Twenty-eight patients (all male; mean age: 70 years, range 52-87 years) placed on 
      LMWH therapy (40 mg subcutaneously every 12 h) for deep venous thrombosis 
      prophylaxis after an operation were included in the study. Transtubular potassium 
      concentration gradient (TTKG) was calculated 1 day prior to LMWH therapy and 
      again after 4 days of treatment. Of the 28 patients enrolled in the study, we 
      were able to calculate the TTKG in only 19 patients: 9 had a urinary osmolarity 
      (either before or after LMWH therapy) less than the serum osmolarity, making the 
      TTKG calculation unreliable. The Wilcoxon signed-rank test was used to analyze 
      differences in the median serum potassium levels and TTKG before and after LMWH 
      therapy. RESULTS: All patients had adequate renal function (creatinine clearance 
      >90 ml/min). Mean (+/- SD) serum potassium concentration before LMWH was 4.25 
      (+/- 0.40) mmol/dl. It increased to 4.35 (+/- 0.41) mmol/dl after initiating LMWH 
      therapy (p = 0.09). Similarly, the mean (+/- SD) TKKG calculated was 5.52 (+/- 
      2.33) before and 5.97 (+/- 3.06) after 4 days of LMWH (p = 0.54). CONCLUSIONS: 
      Unlike UFH, LMWH (Lovenox in doses used for postoperative prophylaxis against 
      deep venous thrombosis does not seem to have a significant effect on potassium 
      homeostasis.
CI  - Copyright 2002 S. Karger AG, Basel
FAU - Abdel-Raheem, Majdi M
AU  - Abdel-Raheem M
AD  - Department of Medicine, University of North Dakota School of Medicine, Fargo, N 
      Dak 58102, USA.
FAU - Potti, Anil
AU  - Potti A
FAU - Tadros, Sherine
AU  - Tadros S
FAU - Koka, Vijay
AU  - Koka V
FAU - Hanekom, David
AU  - Hanekom D
FAU - Fraiman, Genise
AU  - Fraiman G
FAU - Danielson, Byron D
AU  - Danielson BD
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pathophysiol Haemost Thromb
JT  - Pathophysiology of haemostasis and thrombosis
JID - 101142710
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 4964P6T9RB (Aldosterone)
RN  - AYI8EX34EU (Creatinine)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aldosterone/*physiology
MH  - Creatinine/metabolism
MH  - Heparin, Low-Molecular-Weight/adverse effects/*pharmacology
MH  - Homeostasis/drug effects
MH  - Humans
MH  - Hyperkalemia/blood/chemically induced/urine
MH  - Kidney Tubules/drug effects/metabolism
MH  - Male
MH  - Middle Aged
MH  - Orthopedic Procedures
MH  - Osmolar Concentration
MH  - Postoperative Complications/prevention & control
MH  - Potassium/*metabolism
MH  - Venous Thrombosis/prevention & control
MH  - Zona Glomerulosa/drug effects
EDAT- 2002/10/10 04:00
MHDA- 2003/04/08 05:00
CRDT- 2002/10/10 04:00
PHST- 2002/10/10 04:00 [pubmed]
PHST- 2003/04/08 05:00 [medline]
PHST- 2002/10/10 04:00 [entrez]
AID - 65208 [pii]
AID - 10.1159/000065208 [doi]
PST - ppublish
SO  - Pathophysiol Haemost Thromb. 2002 May-Jun;32(3):107-10. doi: 10.1159/000065208.